BSTC - BioSpecifics Technologies: Microcap At Inflection Point Has Upside Potential
Investment Thesis
BioSpecifics Technologies Corp. 5-year share price performance. Source: TradingView
BioSpecifics (BSTC) is a small microcap with a market cap of just $474m and revenues of $38.1m in 2019, but the company is entering an exciting phase in its development with the recent FDA approval of its injectable collagenase clostridium histolyticum ("CCH") treatment for cellulite.
BioSpecifics owns and controls the patents for its CCH, marketed and sold as Xiaflex by Endo International (ENDP) currently as a treatment for Dupuytren's contracture ("DC"), and Peyronie's disease ("PD"), and earns royalty payments in the low